GW Pharmaceuticals

Most Recent

  • Marijuana grower
    Cannabis

    Which Marijuana Stocks Are Popular on Reddit?

    By Adam Goodpasture
  • uploads///herb _
    Company & Industry Overviews

    Curaleaf Opens Medical Marijuana Dispensary in Tallahassee

    On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.

    By Mike Benson
  • uploads///part
    Earnings Report

    How Analysts View Cresco Labs before Its Q1 Release

    Cresco Labs (CRLBF) is slated to release its first-quarter earnings on May 29.

    By Mohit Oberoi, CFA
  • Cannabis

    New Gallup Poll on Marijuana Legalization Support

    A recent Gallup poll data found that nearly 66% of Americans support making cannabis legal. However, this figure was the same as in 2018. This suggests a standstill in the rise in support of cannabis legalization. Moreover, nine states will be voting in 2020 on measures to allow cannabis for recreational or medical use. The […]

    By Anjana Viswanathan
  • uploads///AdobeStock_
    Cannabis

    Cannabis Stocks: What Happens in a Recession?

    As market analysts increasingly predict an upcoming global recession, we take a look at the impact of a recession on cannabis stocks.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    What’s the Market Potential for CBD?

    The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?

    By Margaret Patrick
  • uploads///foliage _
    Company & Industry Overviews

    Comparing GW Pharmaceuticals’ Returns to Peers

    GW Pharmaceuticals has received a “strong buy” rating from four analysts, while eight have rated it as a “buy” or some equivalent.

    By Mohit Oberoi, CFA
  • uploads///texas marijuana
    Cannabis

    Could Marijuana Legalization Help Texas Recover Its Losses?

    Texas has suffered huge economic losses. Many industry experts think that marijuana legalization could be a good option to revive the state’s economy.

    By Sushree Mohanty
  • uploads///cannabis relief
    Cannabis

    Marijuana: Banking Access Included in Coronavirus Relief Bill

    Marijuana companies in the US have been struggling to get financial and banking access. Cannabis still isn’t legal at the federal level.

    By Sushree Mohanty
  • uploads///green thumb store
    Cannabis

    New Cannabis Store Opens before Green Thumb’s Q1 Earnings

    Green Thumb Industries (OTCMKTS:GTBIF) will likely report its results for the first quarter of fiscal 2020 on May 14 after the market closes. 

    By Sushree Mohanty
  • uploads///GW Pharmaceuticals results
    Cannabis

    GW Pharmaceuticals Stock Rises on Higher Epidiolex Sales

    On Monday, GW Pharmaceuticals reported its first-quarter earnings. The company beat analysts’ revenue, EBITDA, and EPS expectations.

    By Rajiv Nanjapla
  • uploads///gw pharmaceuticals target price cut
    Cannabis

    Analysts Cut GW Pharmaceuticals’s Target Price after Q4 Earnings

    On Tuesday, GW Pharmaceuticals reported its fourth-quarter earnings. The company reported revenue of $109.1 million, which beat analysts’ expectations.

    By Rajiv Nanjapla
  • uploads///GWPH_
    Cannabis

    Analyzing GW Pharmaceuticals’ Q4 Earnings and Outlook

    On Tuesday, GW Pharmaceuticals reported its fourth-quarter earnings after the market closed. For the quarter, the company reported revenue of $109.1 million.

    By Rajiv Nanjapla
  • uploads///GW Pharmaceuticals
    Cannabis

    GW Pharmaceuticals Provides Preliminary Sales Update

    On January 12, GW Pharmaceuticals announced its preliminary unaudited product sales report for the fourth quarter and 2019.

    By Rajiv Nanjapla
  • uploads///GWPH
    Cannabis

    Is GW Pharmaceuticals a Good Bet?

    Analysts expect GW Pharmaceuticals to become profitable in 2020. They expect the company’s EBITDA to be $42.8 million in 2020.

    By Rajiv Nanjapla
  • uploads///AdobeStock_
    Cannabis

    Is GW Pharmaceuticals a Good Buy in December 2019?

    GW Pharmaceuticals (GWPH) is a leading player in cannabinoid medicines. The company offers the first FDA-approved plant-derived cannabinoid medicine.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    ACB Focuses on Medical Marijuana Opportunities

    Aurora Cannabis’ (ACB) is receiving a lot of flak from analysts and investors. This happened after its disappointing first-quarter performance.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    NHS Approves Cannabis Medicines: Market Impact

    On November 11, the NHS (National Health Service) approved two cannabis-based medicines, Epidyolex and Sativex, for use in the United Kingdom.

    By Margaret Patrick
  • GW Pharmaceuticals: Analysts’ Ratings, Price Target
    Analyst Price Target

    GW Pharmaceuticals: Analysts’ Ratings, Price Target

    GW Pharmaceuticals (GWPH) recently reported its QA3 results. Although its financials beat estimates, the company’s stock has fallen 18% since then.

    By Nivedha Elango
  • uploads///AdobeStock_
    Cannabis

    GW Pharmaceuticals: Target Price and Valuation Update

    Thirteen analysts are covering GW Pharmaceuticals in October. Nine covered the stock in October 2018. The consensus target price for the stock is $226.85.

    By Margaret Patrick
  • uploads///AdobeStock_
    Cannabis

    UK Approves Another Medicinal Cannabis Product

    GW Pharmaceuticals has announced the European Commission’s approval of EPIDYOLEX. This will mark its entry into all European countries, including the UK.

    By Margaret Patrick
  • uploads///herb _
    Earnings Report

    Analyzing Charlotte’s Web Holdings’ Q1 Earnings Estimates

    Charlotte’s Web Holdings (CWBHF) is scheduled to release its first-quarter earnings today and hold its earnings conference call tomorrow.

    By Mohit Oberoi, CFA
  • uploads///INSY
    Company & Industry Overviews

    How Is INSYS Therapeutics Financially Positioned in January?

    In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.

    By Daniel Collins
  • uploads///flowers _
    Company & Industry Overviews

    Cannabis Stock INSYS Therapeutics Has Risen 28% in January

    On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.

    By Daniel Collins
  • uploads///GW Oppor
    Company & Industry Overviews

    Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

    GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results.

    By Daniel Collins
  • uploads///GWPH Net loss
    Company & Industry Overviews

    How GW Pharmaceuticals’ Earnings Are Trending

    In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively.

    By Daniel Collins
  • uploads///GW revenue
    Company & Industry Overviews

    A Look into GW Pharmaceuticals’ Revenue Trends

    In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.

    By Daniel Collins
  • uploads///herb _
    Company & Industry Overviews

    GW Pharmaceuticals Has Already Soared 23% in January

    GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    GW Pharmaceuticals’ European Launch and Payer Access for Epidiolex

    According to GW’s fiscal 2018 fourth-quarter earnings conference call, it’s planning to launch Epidiolex in five major European markets in 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GW Pharmaceuticals Focuses on Epidiolex’s US Commercial Launch

    On September 5, the US Department of Justice and the DEA issued a press release announcing the rescheduling of Epidiolex into Schedule V of the Controlled Substances Act.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Epidiolex Launch Expected to Push Up GW’s Operating Expenses

    Analysts expect GW Pharmaceuticals to report SG&A (selling, general, and administrative) expenses of $179.14 million in 2019.

    By Margaret Patrick
  • uploads///foliage _
    Earnings Report

    Trulieve to Announce Q3 Earnings on November 19!

    Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET.

    By Mike Benson
  • uploads///seedling _
    Company & Industry Overviews

    How Marijuana-Focused Biotech Companies Have Performed in 2018

    In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GW Pharmaceuticals: Recommendations and Market Capitalization

    Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

    By Mike Benson
  • uploads///marijuana _
    Healthcare

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.

    By Mike Benson
  • uploads///epilepsy _
    Company & Industry Overviews

    GWPH Prepares to Launch Epidiolex in the US Market

    On June 25, GW Pharmaceuticals (GWPH) announced that it received FDA approval for Epidiolex (cannabidiol)—its oral solution.

    By Margaret Patrick
  • uploads///weed _
    Company & Industry Overviews

    Why Cannabis Stock Canopy Growth Surged 12% Yesterday

    The Investment Industry Regulatory Organization of Canada imposed a trading halt on Canopy Growth at 4:11 PM EST on February 16, 2018.

    By Adam Jones
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.